“…The most important and somewhat novel aspects identified by the task force were the following: (1) treatment of dyslipidaemia should not be considered as an isolated process, but rather within the context of integrated prevention of CVD in an individual patient. The SCORE scale is recommended as a basic tool for calculating CV risk; (2) therapeutic objectives: strengthening of strict low-density lipoprotein cholesterol (LDL-C) targets for patients with very high, high, and intermediate risk levels (no longer as an optional criterion) [4][5][6][7]; (3) non-pharmacological therapies: the relevance of diet and exercise not just in the reduction of total risk, but also in the specific treatment of dyslipidaemias [4,8]; (4) lipid-lowering drugs: a logical emphasis on statins as an essential treatment for cardiovascular prevention, and scarce details on fibrates, niacin, and absorption inhibitors; (5) dyslipidaemia treatment in special clinical situations: the detailed description of targets and prescriptions in several situations and subgroups [4,9,10].…”